Vivani Medical, Inc. (VANI)
Vivani Medical, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Alameda, CA, US. The stock last traded at $1.14, up 4.59% on the session, giving a market capitalisation of $102.8M. On trailing twelve-month figures it carries a trailing P/E of -3.56, a net margin of 0.0%. Its beta of 3.32 implies it has historically moved more than the broad market.
Vivani Medical, Inc., a clinical-stage biopharmaceutical company, engages in the development of miniaturized and subdermal drug implants that treat chronic diseases. The company uses its NanoPortal implant technology to develop and potentially commercialize drug implant candidates, alone or in collaboration with pharmaceutical company partners, to address causes of poor clinical outcomes in the treatment of chronic diseases. Its pipeline includes NPM-139 for chronic weight management in patients who are obese or overweight; NPM-133 a semaglutide implant for the treatment of patients with type 2 diabetes; NPM-115, an exenatide implant candidate for chronic weight management in patients who are obese or overweight; and OKV-119, an exenatide implant for the treatment of obesity and diabetes in companion animals, including cats and dogs. The company is headquartered in Alameda, California.
Vivani Medical, Inc. is most often compared with the following Healthcare names: